UMN Pharma Inc., API Co., Ltd., and Yakult Honsha Co., Ltd., today announced that they signed a letter of intent and agreed on a basic framework for co-development and commercialization of biosimilars in the field of oncology. The three companies will hold talks on the details of the joint business and sign an official agreement.